Citations

Mayo Clinic

Showing 10 of 108602 citations.

Craniomaxillofacial Trauma: The Past, Present and the Future
Salinas, Cristina A., Sharaf, Basel , Sharaf, Basel A, Sharaf, Basel A , Morris, Jonathan M.

Journal of Craniofacial Surgery | April 19, 2023 | Volume: 34 | Issue: 5 | Pages: 1427-1430

10.1097/scs.0000000000009334 | PMID 37072888 Get It

Reconstruction of facial trauma has seen a significant evolutionary leap in the last 100 years. The current surgical management of facial fractures was made possible by the efforts and creativity of pioneer surgeons, advances in anatomic understanding, and the continued development of biomaterials and imaging technologies. Virtual surgical planning (VSP) and 3-dimensional printing (3DP) are being incorporated into the management of acute facial trauma. The integration of this technology at the point of care is rapidly expanding globally. This article reviews the history of the management of craniomaxillofacial trauma, current practices, and future directions. The use of VSP and 3DP in facial trauma care is highlighted with a description of EPPOCRATIS, a rapid point-of-care process incorporating VSP and 3DP at the trauma center.
MicroRNA ‐ 19a ‐ 3p Decreases with Age in Mice and Humans and Inhibits Osteoblast Senescence
Kaur, Japneet , Saul, Dominik , Doolittle, Madison L. , Farr, Joshua N. , Khosla, Sundeep , Monroe, David G. , Khosla, Sundeep , Monroe, David G , Farr, Joshua N , Saul, Dominik

JBMR Plus | April 18, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1002/jbm4.10745 | PMID 37283656 Get It

ABSTRACT Aging is a major risk factor for most chronic diseases, including osteoporosis, and is characterized by an accumulation of senescent cells in various tissues. MicroRNAs (miRNAs) are critical regulators of bone aging and cellular senescence. Here, we report that miR ‐ 19a ‐ 3p decreases with age in bone samples from mice as well as in posterior iliac crest bone biopsies of younger versus older healthy women. miR ‐ 19a ‐ 3p also decreased in mouse bone marrow stromal cells following induction of senescence using etoposide, H 2 O 2 , or serial passaging. To explore the transcriptomic effects of miR ‐ 19a ‐ 3p , we performed RNA sequencing of mouse calvarial osteoblasts transfected with control or miR ‐ 19a ‐ 3p mimics and found that miR ‐ 19a ‐ 3p overexpression significantly altered the expression of various senescence, senescence‐associated secretory phenotype‐related, and proliferation genes. Specifically, miR ‐ 19a ‐ 3p overexpression in nonsenescent osteoblasts significantly suppressed p16 Ink4a and p21 Cip1 gene expression and increased their proliferative capacity. Finally, we established a novel senotherapeutic role for this miRNA by treating miR ‐ 19a ‐ 3p expressing cells with H 2 O 2 to induce senescence. Interestingly, these cells exhibited lower p16 Ink4a and p21 Cip1 expression, increased proliferation‐related gene expression, and reduced SA‐β‐Gal+ cells. Our results thus establish that miR ‐ 19a ‐ 3p is a senescence‐associated miRNA that decreases with age in mouse and human bones and is a potential senotherapeutic target for age‐related bone loss. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease
Vasudevan, Abhinav , Tharayil, Vivek, Raffals, Laura H., Bruining, David H. , Becker, Michelle , Murad, Mohammad Hassan, Murad, M. Hassan , Loftus, Edward V.

Inflammatory Bowel Diseases | April 18, 2023 | Volume: 30 | Issue: 4 | Pages: 660-670

10.1093/ibd/izad065 | PMID 37071852 Get It

Abstract Background Optimizing therapy and monitoring response are integral aspects of inflammatory bowel disease treatment. We conducted a systematic review and meta-analysis to determine whether serum ustekinumab trough concentrations during maintenance therapy were associated with ustekinumab treatment response in patients with inflammatory bowel disease. Methods A systematic review was performed to March 21, 2022, to identify studies using MEDLINE, EMBASE, and the Cochrane library. We included studies that reported the association between serum ustekinumab trough concentrations with clinical or endoscopic remission. Outcome measures were combined across studies using the random-effects model with an odds ratio (OR) for binary outcomes of endoscopic and clinical remission. Results We identified 14 observational studies that were included in the analysis for clinical remission (919 patients, 63% with Crohn’s disease) or endoscopic remission (290 patients, all with Crohn’s disease). Median ustekinumab trough concentrations were higher amongst individuals achieving clinical remission compared with those not achieving remission (mean difference, 1.6 ug/mL; 95% confidence interval [CI], 0.21-3.01 ug/mL). Furthermore, individuals with median serum trough concentration in the fourth quartile were significantly more likely to achieve clinical (OR, 3.61; 95% CI, 2.11-6.20) but not endoscopic remission (OR, 4.67; 95% CI, 0.86-25.19) compared with those with first quartile median trough concentrations. Conclusion Based on the results of this meta-analysis primarily relating to patients with Crohn’s disease on maintenance ustekinumab treatment, it appears that there is an association between higher ustekinumab trough concentration and clinical outcomes. Prospective studies are required to determine whether proactive dose adjustments of ustekinumab therapy provides additional clinical benefit.
Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy
Beach, Thomas G. , Sue, Lucia I., Scott, Sarah, Intorcia, Anthony J., Walker, Jessica E. , Arce, Richard, Glass, Michael J. , Borja, Claryssa I., Cline, Madison P. , Hemmingsen, Spencer J, Qiji, Sanaria H., Stewart, Analisa M. , Martinez, Kayleigh N, Krupp, Addison, McHattie, Rylee, Mariner, Monica, Lorenzini, Ileana , Kuramoto, Angela, Long, Kathy E., Tremblay, Cécilia , Caselli, Richard J. , Woodruff, Bryan K. , Rapscak, Steven Z., Belden, Christine M. , Goldfarb, Danielle, Driver‐Dunckley, Erika , Mehta, Shyamal H. , Shill, Holly A. , Driver-Dunckley, Erika D., Adler, C H , Choudhury, Parichita , Sabbagh, Marwan Noel , Atri, Alireza , Adler, Charles H. , Serrano, Geidy E.

Journal of Neuropathology & Experimental Neurology | April 18, 2023 | Volume: 82 | Issue: 6 | Pages: 457-466

10.1093/jnen/nlad026 | PMID 37071794 Get It

Abstract Cerebral white matter rarefaction (CWMR) was considered by Binswanger and Alzheimer to be due to cerebral arteriolosclerosis. Renewed attention came with CT and MR brain imaging, and neuropathological studies finding a high rate of CWMR in Alzheimer disease (AD). The relative contributions of cerebrovascular disease and AD to CWMR are still uncertain. In 1181 autopsies by the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), large-format brain sections were used to grade CWMR and determine its vascular and neurodegenerative correlates. Almost all neurodegenerative diseases had more severe CWMR than the normal control group. Multivariable logistic regression models indicated that Braak neurofibrillary stage was the strongest predictor of CWMR, with additional independently significant predictors including age, cortical and diencephalic lacunar and microinfarcts, body mass index, and female sex. It appears that while AD and cerebrovascular pathology may be additive in causing CWMR, both may be solely capable of this. The typical periventricular pattern suggests that CWMR is primarily a distal axonopathy caused by dysfunction of the cell bodies of long-association corticocortical projection neurons. A consequence of these findings is that CWMR should not be viewed simply as “small vessel disease” or as a pathognomonic indicator of vascular cognitive impairment or vascular dementia.
Additional COVID-19 Booster Doses Increase Anti-spike Serum Antibody Concentrations Among Patients With Inflammatory Bowel Disease
Schell, Trevor , Almasry, Mazen, Caldera, Freddy , Ramirez, Oscar Ramirez , Caldera, Freddy , Schell, Trevor L , Ramirez Ramirez, Oscar , Ramirez, Oscar, Farraye, Francis A. , Hayney, Mary S.

Inflammatory Bowel Diseases | April 18, 2023 | Volume: 29 | Issue: 10 | Pages: e38-e39

10.1093/ibd/izad068 | PMID 37071782 Get It

Three-Dimensional Structure of Inner Ear Hair Cell Ribbon Synapses in a Zebrafish Model of Usher Syndrome Type 1B
Riley, Kenneth C. , Riley, Kenneth C. , Koleilat, Alaa , Dugdale, Joseph , Cooper, Shawna A. , Christensen, Trace , Schimmenti, Lisa A. , Koleilat, Alaa , Dugdale, Joseph A , Cooper, Shawna A , Christensen, Trace A , Schimmenti, Lisa A

Zebrafish | April 18, 2023 | Volume: 20 | Issue: 2 | Pages: 47-54

10.1089/zeb.2022.0049 | PMID 37071854 Get It

Our understanding of inner ear hair cell ultrastructure has heretofore relied upon two-dimensional imaging; however, serial block-face scanning electron microscopy (SBFSEM) changes this paradigm allowing for three-dimensional evaluation. We compared inner ear hair cells of the apical cristae in myo7aa −/− null zebrafish, a model of human Usher Syndrome type 1B, to hair cells in wild-type zebrafish by SBFSEM to investigate possible ribbon synapse ultrastructural differences. Previously, it has been shown that compared to wild type, myo7aa −/− zebrafish neuromast hair cells have fewer ribbon synapses yet similar ribbon areas. We expect the recapitulation of these results within the inner ear apical crista hair cells furthering the knowledge of three-dimensional ribbon synapse structure while resolving the feasibility of therapeutically targeting myo7aa −/− mutant ribbons. In this report, we evaluated ribbon synapse number, volume, surface area, and sphericity. Localization of ribbons and their distance from the nearest innervation were also evaluated. We determined that myo7aa −/− mutant ribbon synapses are smaller in volume and surface area; however, all other measurements were not significantly different from wild-type zebrafish. Because the ribbon synapses are nearly indistinguishable between the myo7aa −/− mutant and wild type, it suggests that the ribbons are structurally receptive, supporting that therapeutic intervention may be feasible.
Good’s Syndrome: Thymoma with Acquired Immunodeficiency
Koo, Chi Wan , Lo, Ying‐Chun

American Journal of Respiratory and Critical Care Medicine | April 18, 2023 | Volume: 208 | Issue: 3 | Pages: 322-324

10.1164/rccm.202211-2159im | PMID 37071872 Get It

Clonally Selected Lines After CRISPR-Cas Editing Are Not Isogenic
Panda, Arijit , Mariani, Jessica , Jang, Yeongjun , Kollmeyer, Thomas M. , Sarkar, Gobinda , Kim, Ji‐Eun , Yoon, Wan Hee , Jenkins, Robert B. , Vaccarino, Flora M. , Abyzov, Alexej , Kollmeyer, Thomas , Vaccarino, Flora M , Abyzov, Alexej , Jang, Yeongjun , Šuvakov, Milovan , Drucker, Kristen , Park, Yohan , Bae, Taejeong

The CRISPR Journal | April 18, 2023 | Volume: 6 | Issue: 2 | Pages: 176-182

10.1089/crispr.2022.0050 | PMID 37071670 Get It

The CRISPR-Cas9 system has enabled researchers to precisely modify/edit the sequence of a genome. A typical editing experiment consists of two steps: (1) editing cultured cells; (2) cell cloning and selection of clones with and without intended edit, presumed to be isogenic. The application of CRISPR-Cas9 system may result in off-target edits, whereas cloning will reveal culture-acquired mutations. We analyzed the extent of the former and the latter by whole genome sequencing in three experiments involving separate genomic loci and conducted by three independent laboratories. In all experiments we hardly found any off-target edits, whereas detecting hundreds to thousands of single nucleotide mutations unique to each clone after relatively short culture of 10–20 passages. Notably, clones also differed in copy number alterations (CNAs) that were several kb to several mb in size and represented the largest source of genomic divergence among clones. We suggest that screening of clones for mutations and CNAs acquired in culture is a necessary step to allow correct interpretation of DNA editing experiments. Furthermore, since culture associated mutations are inevitable, we propose that experiments involving derivation of clonal lines should compare a mix of multiple unedited lines and a mix of multiple edited lines.
The Adverse Effects Profile of Teprotumumab
Stan, Marius N. , Krieger, Christine C.

The Journal of Clinical Endocrinology & Metabolism | April 18, 2023 | Volume: 108 | Issue: 9 | Pages: e654-e662

10.1210/clinem/dgad213 | PMID 37071658 Get It

Abstract Context Teprotumumab therapy for thyroid eye disease (TED) patients represents a major step forward. It targets and inhibits the insulin-like growth factor-1 receptor (IGF-1R), and its effectiveness is based on its interconnectedness with the thyrotropin receptor. However, IGF-1R has a ubiquitous expression and several adverse effects have been reported with teprotumumab use. Objective Describing these adverse effects for better understanding is the purpose of this review. Methods We reviewed the oncological studies in which teprotumumab was initially used. Subsequently we reviewed the clinical trials for TED and then the case series and case reports associated with teprotumumab use since it is US Food and Drug Administration approval (January 2020). We focused on common and/or serious adverse effects reported with the use of teprotumumab. Results We described the common occurrence of hyperglycemia (10%-30% incidence), its risk factors and suggested management. Hearing changes are described, a broad spectrum from mild ear pressure to hearing loss (sensorineural mechanism). Risk factors, suggested monitoring, and possible upcoming therapies are reviewed. We also reviewed data on fatigue, muscle spasms, hair loss, weight loss, gastrointestinal disturbances, menstrual changes, and infusion reactions. We noted some discrepancies between adverse effects in oncological studies vs studies focused on TED, and we aimed to explain these differences. Conclusion The use of teprotumumab should consider patient's values and preferences in balancing the expected benefit with these potential risks. Future drugs targeting IGF-1R should investigate these adverse effects for a possible class effect. Combination therapies with different agents hopefully will be identified that maximize benefits and minimize risks.
Invited Commentary: The Fate of MAPCAs
Cetta, Frank

World Journal for Pediatric and Congenital Heart Surgery | April 18, 2023 | Volume: 14 | Issue: 3 | Pages: 273-274

10.1177/21501351231162913 | PMID 37071568 Get It